Eli Lilly & Co.

Pharmaceuticals
United States
Executive 1Dr. John C. Lechleiter, Ph.D., Chairman; President; Chief Executive Officer | Chairman; President; Chief Executive Officer
Executive 2Mr. Derica W. Rice, ; Executive Vice President; Chief Financial Office | Vice-Chairman; President; Chief Executive Officer
Earnings Per Share Growth (%)-48.38%
Cost of Goods Sold (US$ Millions)$4,933
Current Liabilities (US$ Millions)$11,208
Total Assets (US$ Millions)$12,180
Long Term Debt (Millions)$5,368
Return on Equity13.56%
Revenue (US$ Millions)$19,616
Total Company Assets$37,178
Revenue Growth (%)-15.13%
Net Income (US$ Millions)$2,391
Earnings Per Share (US$)$2.23
Total Equity (US$ Millions)$15,373
Profit Margin (%)12.19%
Debt To Equity Ratio (%)0.35%
Inventories (Millions)$2,740